Equities analysts expect that Becton, Dickinson and Company (NYSE:BDX) will post earnings per share of $2.37 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Becton, Dickinson and’s earnings, with estimates ranging from $2.36 to $2.40. Becton, Dickinson and reported earnings of $2.12 per share during the same quarter last year, which indicates a positive year over year growth rate of 11.8%. The business is expected to announce its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Becton, Dickinson and will report full year earnings of $9.46 per share for the current financial year, with EPS estimates ranging from $9.44 to $9.47. For the next year, analysts anticipate that the business will post earnings of $10.48 per share, with EPS estimates ranging from $10.34 to $10.85. Zacks’ EPS calculations are an average based on a survey of research firms that cover Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business’s revenue was down 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.35 earnings per share.

Several research analysts recently commented on BDX shares. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $195.79.

In other news, EVP Ribo Alberto Mas sold 7,463 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the sale, the executive vice president now directly owns 29,323 shares in the company, valued at approximately $5,905,945.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nabil Shabshab sold 6,149 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the completion of the sale, the insider now owns 15,648 shares in the company, valued at $3,157,140.48. The disclosure for this sale can be found here. Insiders have sold a total of 48,605 shares of company stock worth $9,718,986 in the last three months. Insiders own 1.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BDX. Intl Fcstone Inc. acquired a new stake in Becton, Dickinson and in the 2nd quarter worth approximately $1,846,000. WFG Advisors LP lifted its stake in Becton, Dickinson and by 0.9% during the 2nd quarter. WFG Advisors LP now owns 5,376 shares of the medical instruments supplier’s stock valued at $1,049,000 after acquiring an additional 48 shares during the period. Toronto Dominion Bank lifted its stake in Becton, Dickinson and by 27.1% during the 2nd quarter. Toronto Dominion Bank now owns 88,628 shares of the medical instruments supplier’s stock valued at $17,292,000 after acquiring an additional 18,908 shares during the period. Cetera Investment Advisers acquired a new stake in Becton, Dickinson and during the 2nd quarter valued at approximately $1,897,000. Finally, Advisory Services Network LLC lifted its stake in Becton, Dickinson and by 13.8% during the 2nd quarter. Advisory Services Network LLC now owns 14,141 shares of the medical instruments supplier’s stock valued at $2,759,000 after acquiring an additional 1,711 shares during the period. Institutional investors and hedge funds own 87.42% of the company’s stock.

Shares of Becton, Dickinson and (NYSE:BDX) opened at 199.57 on Friday. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63. The company has a 50 day moving average price of $200.11 and a 200 day moving average price of $190.65. The company has a market capitalization of $45.41 billion, a PE ratio of 57.80 and a beta of 1.06.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.46%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/08/2-37-eps-expected-for-becton-dickinson-and-company-bdx-this-quarter.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.